Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.
Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period
Equals Initial Population
None
Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment
Not Applicable
Patient refused the bone density evaluation at the time ordered or did not have it performed within 3 months after the start of ADT
A higher score indicates better quality
In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for twelve month period (regime/therapy) is the correct code.
This eCQM is a patient-based measure.
This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.
The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.
Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.
Patient refused recommendation for a bone density evaluation after the start of ADT therapy
This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center for more information on the QDM.
Updated copyright.
Measure Section: Copyright
Source of Change: Annual Update
Removed reference to a value set within the definition to point to the terminology section as the source of truth.
Measure Section: Definition
Source of Change: Measure Lead
Updated grammar and formatting to improve readability.
Revised grammar in reference to First Androgen Deprivation Therapy.
Updated version number of the Quality Data Model (QDM) used in the measure specification to v5.6.
Measure Section: Guidance
Source of Change: Standards/Technical Update
Revised the narrative to better align with the logic.
Measure Section: Denominator Exceptions
Added definition 'First ADT During Measurement Period and Order for 12 Months of ADT During Measurement Period' to correctly capture the initial population, and properly anchor the first ADT and the order for intended 12 months of treatment.
Measure Section: Definitions
Replaced definition 'Androgen Deprivation Therapy Start Date With Prostate Cancer And Intended 12 Months Therapy' definition and logic to accurately capture measure intent of linking the ADT, prostate cancer diagnosis, and the provider's intention to continue treatment for 12 months.
Revised the timing in the 'Prostate Cancer Diagnosis' definition by replacing the timing of 'same day or before end' with 'overlaps' to anchor the timing of prostate cancer to the measurement period.
Source of Change: ONC Project Tracking System (JIRA): CQM-4761
Updated the names of CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.
Measure Section: Multiple Sections
Updated the version number of the Measure Authoring Tool (MAT) Global Common Functions Library to v7.0.000.
Updated the version of the Quality Data Model (QDM) to 5.6 and Clinical Quality Language (CQL) to 1.5.
The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.
Replaced value set Patient Declined (2.16.840.1.113883.3.600.791) with value set Patient Declined (2.16.840.1.113883.3.526.3.1582) based on new or changed coding guidelines.
Measure Section: Terminology